



Ozempic (Semaglutide) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF](https://magellanrx.com/member/external/commercial/common/doc/en-us/phi_disclosure_authorization.pdf)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
 AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY <input type="checkbox"/> RENEWAL		IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





Ozempic (Semaglutide) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? YES (if yes, complete below) NO

MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:

2. LIST DIAGNOSES: **ICD-10:**

<input type="checkbox"/> Type II diabetes <input type="checkbox"/> Type II diabetes with established cardiovascular disease <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____ _____	
--	--

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Lab Values:
Was the patient's most recent HbA1c in the past 6 months or prior to starting the requested medication 7.0% or greater? Yes No
Documentation of HbA1c level required.

Is the patient's estimated glomerular filtration rate (GFR) less than or equal to 45 mL/min/1.73 m2? Yes No
Documentation of GFR required.

Does the patient currently have a serum creatinine level exceeding 1.8 mg/dL or an estimated GFR less than 30 mL/min/1.73 m2? Yes No
Documentation required.

Clinical information:
Does the patient have advanced liver disease with at least one of the following? Yes No
If yes, please select:
 Ascites
 Cirrhosis
 Hepatic encephalopathy
 Portal hypertension

Does the patient have a history of sulfa-induced Stevens-Johnson syndrome, sulfa-induced toxic epidermal necrolysis, OR sulfa allergy? Yes No

Does the patient have a history of falls OR is the patient at high risk for falls? Yes No

Medication information:
Is the patient currently taking AND will continue to take insulin and/or warfarin? Yes No

Has the patient tried or is the patient currently taking metformin? Yes No

Has treatment with metformin been avoided due to lactic acidosis or elevated liver enzymes? Yes No





Ozempic (Semaglutide) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Has the patient tried or is the patient currently receiving treatment with at least one of the following? Yes No

If yes, please select:

- Glimepiride
- Glipizide
- Glyburide
- Nateglinide
- Repaglinide

Has treatment with glimepiride, glipizide, glyburide, nateglinide, or repaglinide been avoided due to any of the following? Yes No

If yes, please select:

- Advanced age
- Elevated liver enzymes or mild/moderate liver disease
- Obesity or overweight state

Is the patient currently taking any of the following medications? Yes No

If yes, please select:

- Janumet/Janumet XR (sitagliptin/metformin)
- Januvia (sitagliptin)
- Jentadueto/Jentadueto XR (linagliptin/metformin) Kazano (alogliptin/metformin)
- Kombiglyze XR (saxagliptin/metformin)
- Nesina (alogliptin)
- Onglyza (saxagliptin)
- Oseni (alogliptin/pioglitazone)
- Tradjenta (linagliptin)
- Glyxambi(empagliflozin/linagliptin)
- Seglujan(ertugliflozin/sitagliptin)
- Qtern(dapagliflozin/saxagliptin)

If the patient is taking any of the above medications, will concomitant therapy with those medications be discontinued? Yes No

Is patient 50 years of age or older with established cardiovascular disease characterized by at least one of the following? Yes No *Please submit chart documentation.*

- History of MI or stroke or transient ischemic attack
- History of unstable angina with ECG changes
- History of coronary revascularization procedure
- History of carotid revascularization procedure
- History of peripheral revascularization procedure
- History of symptomatic coronary heart disease documented by positive stress test, or cardiac imaging
- Patient has more than 50% stenosis on angiography or imaging of coronary, carotid or lower extremities arteries
- Patient has asymptomatic cardiac ischemia documented by positive nuclear imaging test or exercise test or stress echo or any cardiac imaging
- Patient has chronic heart failure NYHA class II or III





**Ozempic (Semaglutide)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Chronic renal impairment documented by eGFR below 60ml/min/1.73m² per modification of diet in renal disease(MDRD)

Is patient 60 years of age or older AND has at least 1 or more of the following risk factors? Yes No *Please submit chart documentation.*

- Persistent microalbuminuria (30.299mg/g) or proteinuria
- Hypertension and left ventricular hypertrophy by ECG or imaging
- Left ventricular systolic or diastolic dysfunction by imaging
- Ankle/brachial index less than 0.9

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program; c/o Magellan Health, Inc.
4801 E. Washington Street, Phoenix, AZ 85034
Phone: 877-228-7909

